Trial Profile

Phase 1b proof-of-concept clinical trial of OLN324 in patients with either wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME) (JADE)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jan 2026 According to an Innovent Biologics media release, full results from this trial will be presented for the first time at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026.
08 Jan 2026 According to an Innovent Biologics media release, company's partner Ollin plans to discuss the JADE study during its upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference, on Tuesday, January 13, 2026.
08 Jan 2026 Results presented in the Innovent Biologics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com